NAD Supplementation in Parkinson's Disease

Part of paid clinical trials in Oklahoma City, Oklahoma.

Sponsor
University of Oklahoma
Study ID
NCT07703137
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
55 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Nicotinamide Riboside (NR) — DIETARY_SUPPLEMENT
    Participants will be randomized to receive either oral nicotinamide riboside at a total daily dose of 1 g or an identically appearing placebo for 12 weeks.
  • Oral placebo capsules — DIETARY_SUPPLEMENT
    1 g identically appearing placebo capsule

Study Details

The goal of this clinical trial is to learn whether Nicotinamide Riboside, a form of Vitamin B3 also known as NR, can improve blood vessel health in the brain, memory, and physical function in eligible study participants. NR is considered investigational for this study because it is not yet established for this specific use. The main questions it aims to answer are: Can NR improve non-invasive measures of blood vessel health in the brain? Can NR improve memory testing results and physical function? Researchers will compare participants who receive NR with participants who receive a placebo, an inactive substance that looks like the study drug, to see if NR has beneficial effects. Participants will be randomly assigned to receive either NR or placebo. They will complete 3 study visits over 13 weeks at the Translational Geroscience Laboratory at the University of Oklahoma Health Campus. During the visits, participants will complete questionnaires, memory testing, non-invasive blood vessel measurements, physical function tests, and a blood draw.

Key Dates

First listed
Jul 14, 2026
Start date
Aug 10, 2026
Status verified
Aug 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • Active Comparator: Active intervention
    Participants will be randomized to receive either oral nicotinamide riboside at a total daily dose of 1 g or an identically appearing placebo for 12 weeks.
  • Placebo Comparator: Placebo intervention
    Participants assigned to the placebo arm will take an oral placebo capsule daily for 12 weeks. The placebo will appear identical to the nicotinamide riboside capsules.

Primary Outcome Measure

Change in task-evoked neurovascular coupling response measured by functional near-infrared spectroscopy [ Time Frame: Baseline to 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Center for Geroscience and Healthy Brain AgingOklahoma CityOklahoma73117-

Find similar trials in Oklahoma City, OK

Nationwide
Parkinson's disease trialsNeurology trialsBrain disorders trials
By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
Center for Geroscience and Healthy Brain Aging· Oklahoma City, OK

Related Studies